一个双对应的血的DNA Aptamer的抗血效应
Yanxi Chen1, Shoubo Xiang2,3, Chunfa Chen1
1College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
ACS biomaterials science & engineering
|April 9, 2025
概括
一种新型的DNA吸收剂有效地抑制了血栓,减少了血块形成和血小板激活. 这种双价阿胺 (bApt) 通过调节血栓蛋白酶激活受体1 (PAR1) 途径,显示出对治疗血栓性疾病的希望.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血凝素是凝血和血小板激活的核心.
- 氨酸蛋白酶激活受体1 (PAR1) 信号驱动血栓形成,复原和动脉样硬化.
- 抑制血栓激素为血栓性疾病提供了一种治疗策略.
研究的目的:
- 为了研究针对血栓的双价DNA吸收体 (bApt) 的抗血栓作用.
- 评估bApt调节血栓-PAR1信号通路的能力.
- 在血栓形成的临床前模型中评估bApt的疗效.
主要方法:
- 设计和合成一种具有酸骨干修饰的双价DNA吸收体 (bApt).
- 在体外评估bApt对凝血参数的影响 (R,K,MA,α,TT,APTT).
- 在动脉损伤模型中对bApt的体内评估,以评估血栓形成.
主要成果:
- bApt剂量取决于延长的凝血时间 (R,K,TT,APTT) 和减少的凝血角度 (α).
- bApt抑制了血小板聚合和血管光滑肌细胞 (VSMC) 的增殖.
- 在动脉损伤模型中观察到血栓形成的显著减少.
结论:
- 双价DNA合体 (bApt) 有效地抑制血栓并调节血栓-PAR1通路.
- bApt在体外和体内表现出显著的抗血栓性质.
- bApt具有作为治疗血栓性疾病管理的治疗剂的潜力.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
417
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
417
DNA Base Pairing
26.6K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
26.6K


